Published in Immunity on December 01, 1997
Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol (2005) 9.72
Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res (2007) 5.51
Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci U S A (2003) 5.49
Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4. Science (2011) 4.96
Checkpoint blockade in cancer immunotherapy. Adv Immunol (2006) 4.09
Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res (2011) 3.81
Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4. Science (2014) 2.95
Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer. J Immunother (2005) 2.84
Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanoma. J Exp Med (2008) 2.60
From genes to drugs: targeted strategies for melanoma. Nat Rev Cancer (2012) 2.46
Disruption of T cell homeostasis in mice expressing a T cell-specific dominant negative transforming growth factor beta II receptor. J Exp Med (2000) 2.45
The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses. Nat Rev Immunol (2011) 2.36
Regulating the regulators: costimulatory signals control the homeostasis and function of regulatory T cells. Immunol Rev (2009) 2.00
Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy. Semin Oncol (2010) 1.98
Chronic immune activation associated with chronic helminthic and human immunodeficiency virus infections: role of hyporesponsiveness and anergy. Clin Microbiol Rev (2004) 1.95
VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses. J Exp Med (2011) 1.77
CTLA-4 blockade in tumor models: an overview of preclinical and translational research. Cancer Immun (2013) 1.71
Cytotoxic T lymphocyte antigen-4 (CTLA-4) regulates primary and secondary peptide-specific CD4(+) T cell responses. Proc Natl Acad Sci U S A (1999) 1.70
The Scurfy mutation of FoxP3 in the thymus stroma leads to defective thymopoiesis. J Exp Med (2005) 1.70
Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo. J Immunol (2014) 1.58
Costimulatory and coinhibitory receptors in anti-tumor immunity. Immunol Rev (2009) 1.44
A case report of Grover's disease from immunotherapy-a skin toxicity induced by inhibition of CTLA-4 but not PD-1. J Immunother Cancer (2016) 1.37
Exploiting CTLA-4, PD-1 and PD-L1 to reactivate the host immune response against cancer. Br J Cancer (2013) 1.32
Cutting edge: CTLA-4--B7 interaction suppresses Th17 cell differentiation. J Immunol (2010) 1.26
Lack of intrinsic CTLA-4 expression has minimal effect on regulation of antiviral T-cell immunity. J Virol (2006) 1.25
Do CD4+ CD25+ immunoregulatory T cells hinder tumor immunotherapy? J Immunother (2002) 1.25
Surface cytotoxic T lymphocyte-associated antigen 4 partitions within lipid rafts and relocates to the immunological synapse under conditions of inhibition of T cell activation. J Exp Med (2002) 1.24
Dual function of CTLA-4 in regulatory T cells and conventional T cells to prevent multiorgan autoimmunity. Proc Natl Acad Sci U S A (2010) 1.23
At the bench: preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy. J Leukoc Biol (2013) 1.21
Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) can regulate dendritic cell-induced activation and cytotoxicity of CD8(+) T cells independently of CD4(+) T cell help. J Exp Med (1999) 1.18
Treg and CTLA-4: two intertwining pathways to immune tolerance. J Autoimmun (2013) 1.18
CTLA-4 dysregulation of self/tumor-reactive CD8+ T-cell function is CD4+ T-cell dependent. Blood (2006) 1.14
CTLA-4 polymorphisms and systemic lupus erythematosus (SLE): a meta-analysis. Hum Genet (2005) 1.14
Rescue of the autoimmune scurfy mouse by partial bone marrow transplantation or by injection with T-enriched splenocytes. Clin Exp Immunol (2003) 1.12
Role of T lymphocytes in tumor response to radiotherapy. Front Oncol (2012) 1.12
CD28, CTLA-4 and their ligands: who does what and to whom? Immunology (2000) 1.10
Modeling CTLA4-linked autoimmunity with RNA interference in mice. Proc Natl Acad Sci U S A (2006) 1.08
Role of CD28 in fatal autoimmune disorder in scurfy mice. Blood (2007) 1.04
CD28 function: a balance of costimulatory and regulatory signals. J Clin Immunol (2002) 1.04
Immunomodulatory therapy for melanoma: ipilimumab and beyond. Clin Dermatol (2013) 1.04
Donor-derived, tolerogenic dendritic cells suppress immune rejection in the indirect allosensitization-dominant setting of corneal transplantation. J Leukoc Biol (2012) 1.02
Modulation of susceptibility to HIV-1 infection by the cytotoxic T lymphocyte antigen 4 costimulatory molecule. J Exp Med (2000) 1.01
Defective CTLA-4 cycling pathway in Chediak-Higashi syndrome: a possible mechanism for deregulation of T lymphocyte activation. Proc Natl Acad Sci U S A (1999) 1.00
CTLA-4 trafficking and surface expression. Trends Immunol (2008) 1.00
Immune regulatory antibodies: are they the next advance? Cancer J (2010) 0.97
Advances in immunotherapy for treatment of lung cancer. Cancer Biol Med (2015) 0.95
CD28 and ITK signals regulate autoreactive T cell trafficking. Nat Med (2013) 0.93
Lack of a role for transforming growth factor-beta in cytotoxic T lymphocyte antigen-4-mediated inhibition of T cell activation. Proc Natl Acad Sci U S A (2001) 0.92
Exploiting synergy: immune-based combinations in the treatment of prostate cancer. Front Oncol (2014) 0.91
Elimination of both CD4+ and CD8+ T cells but not B cells eliminates inflammation and prolongs the survival of TGFbeta1-deficient mice. Cell Immunol (2005) 0.91
The biologic importance of tumor-infiltrating lymphocytes. J Cutan Pathol (2010) 0.90
Profile of ipilimumab and its role in the treatment of metastatic melanoma. Drug Des Devel Ther (2011) 0.90
Optimal management of metastatic melanoma: current strategies and future directions. Am J Clin Dermatol (2013) 0.86
Humanized mice as a model for aberrant responses in human T cell immunotherapy. J Immunol (2014) 0.86
Targeting PD-1/PD-L1 in lung cancer: current perspectives. Lung Cancer (Auckl) (2015) 0.86
T cell costimulation and coinhibition: genetics and disease. Discov Med (2011) 0.85
Anti-cytotoxic T lymphocyte antigen-4 antibodies in melanoma. Clin Cosmet Investig Dermatol (2013) 0.85
Implementing combinatorial immunotherapeutic regimens against cancer: The concept of immunological conditioning. Oncoimmunology (2014) 0.84
Fcγ receptors enable anticancer action of proapoptotic and immune-modulatory antibodies. J Exp Med (2013) 0.84
CD28 family and chronic rejection: "to belatacept...And beyond!". J Transplant (2012) 0.82
Blimp-1 connects the intrinsic and extrinsic regulation of T cell homeostasis. J Clin Immunol (2007) 0.80
CTLA-4 interacts with STAT5 and inhibits STAT5-mediated transcription. Immunology (2006) 0.80
Evidence for CTLA4 as a susceptibility gene for dilated cardiomyopathy. Eur J Hum Genet (2010) 0.80
Modulation of CTLA-4 and GITR for cancer immunotherapy. Curr Top Microbiol Immunol (2011) 0.80
Differences in the regulation of CD4 and CD8 T-cell clones during immune responses. Philos Trans R Soc Lond B Biol Sci (2000) 0.79
Global T cell dysregulation in non-autoimmune-prone mice promotes rapid development of BAFF-independent, systemic lupus erythematosus-like autoimmunity. J Immunol (2008) 0.79
Negative immune checkpoints on T lymphocytes and their relevance to cancer immunotherapy. Mol Oncol (2015) 0.79
Identifying functional defects in patients with immune dysregulation due to LRBA and CTLA-4 mutations. Blood (2017) 0.78
Systemic Therapy for Merkel Cell Carcinoma: What's on the Horizon? Cancers (Basel) (2014) 0.77
Immune Checkpoint Modulators: An Emerging Antiglioma Armamentarium. J Immunol Res (2016) 0.77
The Role of Alternative Splicing in the Control of Immune Homeostasis and Cellular Differentiation. Int J Mol Sci (2015) 0.76
Cell Type-Specific Regulation of Immunological Synapse Dynamics by B7 Ligand Recognition. Front Immunol (2016) 0.75
Correlation between CTLA-4 gene rs221775A>G single nucleotide polymorphism and multiple sclerosis susceptibility. A meta-analysis. Open Med (Wars) (2016) 0.75
Immunometabolic Regulations Mediated by Coinhibitory Receptors and Their Impact on T Cell Immune Responses. Front Immunol (2017) 0.75
Cancer immunotherapy innovator James Allison receives the 2015 Lasker~DeBakey Clinical Medical Research Award. J Clin Invest (2015) 0.75
Immunological phenotype of the murine Lrba knockout. Immunol Cell Biol (2017) 0.75
Concurrent OX40 and CD30 Ligand Blockade Abrogates the CD4-Driven Autoimmunity Associated with CTLA4 and PD1 Blockade while Preserving Excellent Anti-CD8 Tumor Immunity. J Immunol (2017) 0.75
Enhancement of antitumor immunity by CTLA-4 blockade. Science (1996) 17.94
CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med (1995) 8.31
CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones. Nature (1992) 7.15
CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells. J Exp Med (1996) 6.13
Tumor-specific antigen of murine T-lymphoma defined with monoclonal antibody. J Immunol (1982) 5.92
The emerging role of CTLA-4 as an immune attenuator. Immunity (1997) 5.35
ICOS co-stimulatory receptor is essential for T-cell activation and function. Nature (2001) 5.32
Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. Science (1993) 5.30
CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. Annu Rev Immunol (2001) 5.17
Limited diversity of gamma delta antigen receptor genes of Thy-1+ dendritic epidermal cells. Cell (1988) 3.88
Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) regulates the unfolding of autoimmune diabetes. J Exp Med (1998) 3.70
CTLA-4-Mediated inhibition of early events of T cell proliferation. J Immunol (1999) 3.49
Developmentally ordered appearance of thymocytes expressing different T-cell antigen receptors. Nature (1988) 3.48
Identification and distribution of the costimulatory receptor CD28 in the mouse. J Immunol (1992) 3.37
Orbital venous anomalies. Ophthalmology (1997) 3.25
Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. Cancer Res (2000) 2.89
CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma. Proc Natl Acad Sci U S A (1998) 2.78
Costimulatory regulation of T cell function. Curr Opin Cell Biol (1999) 2.69
Nontraumatic subperiosteal orbital hemorrhage. Ophthalmology (2001) 2.55
Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer. Proc Natl Acad Sci U S A (1997) 2.53
The T cell antigen receptor complex expressed on normal peripheral blood CD4-, CD8- T lymphocytes. A CD3-associated disulfide-linked gamma chain heterodimer. J Exp Med (1987) 2.52
Recognition of self antigens by skin-derived T cells with invariant gamma delta antigen receptors. Science (1991) 2.49
Expression and function of the CD3-antigen receptor on murine CD4+8+ thymocytes. Nature (1987) 2.38
Biphasic and protracted anaphylaxis. J Allergy Clin Immunol (1986) 2.36
Co-stimulation in T cell responses. Curr Opin Immunol (1997) 2.35
Illness behavior and the sick role in chronic disease. The case of multiple sclerosis. Soc Sci Med (1982) 2.25
Precision and accuracy of commercial laboratories' ability to classify positive and/or negative allergen-specific IgE results. Ann Allergy Asthma Immunol (2001) 2.23
The role of CTLA-4 in the regulation and initiation of T-cell responses. Immunol Rev (1996) 2.18
Structure, function, and serology of the T-cell antigen receptor complex. Annu Rev Immunol (1987) 2.17
Biomechanics of baseball pitching. A preliminary report. Am J Sports Med (1985) 2.08
Modulation of cyclic AMP in purified rat mast cells. I. Responses to pharmacologic, metabolic, and physical stimuli. J Immunol (1975) 2.07
Potentiation of mast cell mediator release by adenosine. J Immunol (1978) 2.05
The mouse T cell receptor: structural heterogeneity of molecules of normal T cells defined by xenoantiserum. Cell (1983) 2.04
Regulation of T-cell receptor gamma-chain RNA expression in murine Thy-1+ dendritic epidermal cells. Nature (1987) 2.00
Disability resulting from occupational low back pain. Part I: What do we know about primary prevention? A review of the scientific evidence on prevention before disability begins. Spine (Phila Pa 1976) (1996) 1.97
CD28-B7 interactions allow the induction of CD8+ cytotoxic T lymphocytes in the absence of exogenous help. J Exp Med (1993) 1.93
Determinants of duration of disability and return-to-work after work-related injury and illness: challenges for future research. Am J Ind Med (2001) 1.79
Identification of antigen receptor-associated structures on murine T cells. Nature (1985) 1.79
Disability resulting from occupational low back pain. Part II: What do we know about secondary prevention? A review of the scientific evidence on prevention after disability begins. Spine (Phila Pa 1976) (1996) 1.76
The murine homologue of the T lymphocyte antigen CD28. Molecular cloning and cell surface expression. J Immunol (1990) 1.74
Origin of Thy-1+ dendritic epidermal cells of adult mice from fetal thymic precursors. Nature (1990) 1.73
Distinct antigen receptor repertoires of two classes of murine epithelium-associated T cells. Nature (1989) 1.73
Transfection of the malaria parasite and expression of firefly luciferase. Proc Natl Acad Sci U S A (1993) 1.70
Murine Ia and human DR antigens: homology of amino-terminal sequences. Proc Natl Acad Sci U S A (1978) 1.70
Cytotoxic T lymphocyte antigen-4 (CTLA-4) regulates primary and secondary peptide-specific CD4(+) T cell responses. Proc Natl Acad Sci U S A (1999) 1.70
Superantigen responses and co-stimulation: CD28 and CTLA-4 have opposing effects on T cell expansion in vitro and in vivo. Int Immunol (1996) 1.69
Thymocyte development is normal in CTLA-4-deficient mice. Proc Natl Acad Sci U S A (1997) 1.67
Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapy. Proc Natl Acad Sci U S A (1999) 1.61
The TRAMP mouse as a model for prostate cancer. Curr Protoc Immunol (2001) 1.57
Activation of phospholipid metabolism during mediator release from stimulated rat mast cells. J Immunol (1979) 1.54
Modulation of cyclic AMP in purified rat mast cells. II. Studies on the relationship between intracellular cyclic AMP concentrations and histamine release. J Immunol (1975) 1.52
Limited diversity of T-cell receptor gamma-chain expression of murine Thy-1+ dendritic epidermal cells revealed by V gamma 3-specific monoclonal antibody. Proc Natl Acad Sci U S A (1989) 1.49
Branch retinal artery occlusion in a child. Aust N Z J Ophthalmol (1996) 1.49
In vivo blockade of CTLA-4 enhances the priming of responsive T cells but fails to prevent the induction of tumor antigen-specific tolerance. Proc Natl Acad Sci U S A (1999) 1.48
Desensitization of patients allergic to penicillin using orally administered beta-lactam antibiotics. J Allergy Clin Immunol (1982) 1.48
Secondary but not primary T cell responses are enhanced in CTLA-4-deficient CD8+ T cells. Eur J Immunol (1998) 1.45
Analytic precision and accuracy of commercial immunoassays for specific IgE: establishing a standard. J Allergy Clin Immunol (2000) 1.44
Mutualistic asexual endophytes in a native grass are usually parasitic. Am Nat (2003) 1.44
Delta is the Cx-gene product in the gamma/delta antigen receptor of dendritic epidermal cells. Nature (1988) 1.41
Floppy eyelid syndrome and mental retardation. Ophthalmology (2000) 1.39
Two signals are required for negative selection of CD4+CD8+ thymocytes. J Immunol (1993) 1.39
Skin testing to detect penicillin allergy. J Allergy Clin Immunol (1981) 1.37
Cardiac disorders in penicillin-induced anaphylaxis. Association with intravenous epinephrine therapy. JAMA (1982) 1.37
Interaction of CTLA-4 with AP50, a clathrin-coated pit adaptor protein. Proc Natl Acad Sci U S A (1997) 1.36
Penicillin allergy and desensitization in serious infections during pregnancy. N Engl J Med (1985) 1.36
Correlation of cell surface antigen expression on human thymocytes by multi-color flow cytometric analysis: implications for differentiation. J Immunol (1986) 1.33
Monoclonal antibodies recognizing oval cells induced in the liver of rats by N-2-fluorenylacetamide or ethionine in a choline-deficient diet. Cancer Res (1985) 1.32
Pinpointing when T cell costimulatory receptor CTLA-4 must be engaged to dampen diabetogenic T cells. Proc Natl Acad Sci U S A (2000) 1.31
Human DR (Ia-like) antigens: biological and molecular profile. Contemp Top Mol Immunol (1978) 1.31
Activation and differentiation requirements of primary T cells in vitro. Proc Natl Acad Sci U S A (1993) 1.29
Squamous cell carcinoma of the eyelids. Br J Ophthalmol (2002) 1.29
Primary localised amyloidosis of the orbit. Br J Ophthalmol (1996) 1.28
Cancer immunotherapy: co-stimulatory agonists and co-inhibitory antagonists. Clin Exp Immunol (2009) 1.28
Phenotypic analysis and gamma delta-T cell receptor repertoire of murine T cells associated with the vaginal epithelium. J Immunol (1991) 1.28
Modulation of cyclic AMP in purified rat mast cells. III. Studies on the effects of concanavalin A and anti-IgE on cyclic AMP concentrations during histamine release. J Immunol (1976) 1.26
Selective depletion of myelin-reactive T cells with the anti-OX-40 antibody ameliorates autoimmune encephalomyelitis. Nat Med (1996) 1.25
Specific blockade of CTLA-4/B7 interactions results in exacerbated clinical and histologic disease in an actively-induced model of experimental allergic encephalomyelitis. J Neuroimmunol (1997) 1.24
Possible role of arachidonic acid and its metabolites in mediator release from rat mast cells. J Immunol (1979) 1.23
CD28-mediated costimulation is necessary for optimal proliferation of murine NK cells. J Immunol (1994) 1.18
A subset of T cell receptors associated with L3T4 molecules mediates C6VL leukemia cell binding of its cognate retrovirus. Cell (1987) 1.15
Concanavalin A-induced histamine release from normal rat mast cells. J Immunol (1975) 1.15
The intertrochanteric hip fracture. A retrospective analysis. Orthopedics (1988) 1.14
Survival after rhino-orbital-cerebral mucormycosis in an immunocompetent patient. Ophthalmology (2000) 1.13
Cytotoxic T lymphocyte antigen-4 (CTLA-4) regulates the size, reactivity, and function of a primed pool of CD4+ T cells. Proc Natl Acad Sci U S A (2000) 1.13
Distinct epitopes on the T cell antigen receptor of HPB-ALL tumor cells identified by monoclonal antibodies. J Immunol (1986) 1.12
Monoclonal antibodies to immunoglobulin G4 induce histamine release from human basophils in vitro. J Allergy Clin Immunol (1982) 1.12
Organ-specific inhibition of metastatic colon carcinoma by CXCR3 antagonism. Br J Cancer (2009) 1.12
Diacylglycerol metabolism in mast cells: a potential role in membrane fusion and arachidonic acid release. J Exp Med (1979) 1.10
Pathogenesis and management of allergic reactions to penicillin and other beta-lactam antibiotics. Pediatr Infect Dis (1983) 1.10
Identification of dipeptidyl peptidase IV as a protein shared by the plasma membrane of hepatocytes and liver biomatrix. Exp Cell Res (1985) 1.09
Specificity and longevity of antitumor immune responses induced by B7-transfected tumors. Cancer Res (1994) 1.08
T-cell activation: integration of signals from the antigen receptor and costimulatory molecules. Immunol Today (1995) 1.07
Cyclic AMP and the immune response;. Adv Cyclic Nucleotide Res (1974) 1.07